Celldex Therapeutics, Inc.

CLDXNasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$1.5M

▼ 78.0% YoY

Net Income

-$258.8M

▼ 63.9% YoY

EPS

$-3.90

▼ 59.2% YoY

Cash

$28.9M

▲ 1.8% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.